Patterns of Care in Cancer Medicine - 2007 · Vol 4

AUDIO PROGRAM GUIDE

To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.

Clifford Hudis, MD
Chief, Breast Cancer Medicine Service
Solid Tumor Division
Memorial Sloan-Kettering Cancer Center
New York, New York

Adjuvant Systemic Therapy

Track 1	Adjuvant hormonal therapy for postmenopausal women with low-risk, early breast cancer
Track 2	Adjuvant hormonal therapy for premenopausal patients with hormone receptor-positive disease
Track 3	Extended adjuvant hormonal therapy beyond five years
Track 4	Optimal duration of adjuvant aromatase inhibitor therapy
Track 5	TAILORx (Trial Assigning IndividuaLized Options for Treatment [Rx]) study
Track 6	Clinical use of the Oncotype DX™ assay
Track 7	MINDACT trial with the MammaPrint^® multigene assay
Track 8	Selection of adjuvant chemotherapy for women with lower-risk, HER2-negative tumors
Track 9	Use of adjuvant docetaxel/cyclophosphamide (TC)
Track 10	Controversies in the treatment of HER2-positive, node-negative tumors smaller than one centimeter
Track 11	Selection of chemotherapy to combine with adjuvant trastuzumab
Track 12	Cardiotoxicity associated with adjuvant chemotherapy and trastuzumab
Track 13	Adjuvant docetaxel/carboplatin/trastuzumab (TCH)
Track 14	Use of adjuvant trastuzumab as monotherapy


	Robert W Carlson, MD Professor of Medicine Division of Oncology and Stanford Medical Informatics Stanford University Medical Center Stanford, California

Treatment of Metastatic Disease

Track 15	Monthly versus every three-month ovarian suppression in premenopausal patients
Track 16	First-line hormonal therapy for postmenopausal women with metastatic disease
Track 17	EFECT trial: Fulvestrant versus exemestane after progression on a nonsteroidal aromatase inhibitor
Track 18	TAnDEM trial data and treatment of hormone receptor-positive, HER2-positive, metastatic disease
Track 19	Use of nanoparticle albumin-bound (nab) paclitaxel for the treatment of metastatic disease
Track 20	Use of premedications with taxanes
Track 21	Incorporation of bevacizumab into the treatment of metastatic breast cancer


	TOP OF PAGE \| PATTERNS OF CARE